Computed tomography (CT)-based measures of calcification in the abdominal aorta are strong predictors of heart attacks and other adverse cardiovascular events — stronger even than the widely used Framingham risk score. These assertions are according to a new study published in the journal Radiology.

October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom ...

Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life expectancy in adults with type 2 diabetes and established cardiovascular disease. Using actuarial methods, and assuming that the demonstrated beneficial effects of Jardiance remain consistent with long-term use, Jardiance was estimated to extend life expectancy by 1 to 4.5 years on average, depending on age, when compared with placebo. This analysis suggests that treatment with Jardiance could add years of life. The results were published in the journal Circulation.

Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those most at risk for 30-day readmission, researchers from UT Southwestern found.

Endologix Inc. received notice that the U.S. Food and Drug Administration (FDA) has classified a voluntary recall action that Endologix took in July of this year as a Class I recall. The July recall involved Endologix’s issuance of a Safety Notice to healthcare professionals (HCPs) using the AFX Endovascular AAA System.